

Attorney Docket No.: DEX-0293
Inventors: Salceda et al.
Serial No.: 09/995,494
Filing Date: November 27, 2001
Page 10

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1: (currently amended) An isolated prostate cancer specific nucleic acid molecule comprising

(a) ~~a nucleic acid molecule comprising~~ a nucleic acid sequence ~~that encodes an amino acid sequence of~~ encoding SEQ ID NO: ~~70 through 115~~ 96;

(b) ~~a nucleic acid molecule comprising a nucleic acid sequence of~~ SEQ ID NO: ~~1 through 69~~ 42 or 43;

(c) a nucleic acid molecule that selectively hybridizes under stringent hybridization conditions of 50% formamide/6X SSC at 42°C for at least 10 hours or 6X SSC at 68°C without formamide for at least 10 hours to the nucleic acid molecule of (a) or (b);
or

(d) a nucleic acid molecule having at least ~~60%~~ 90% sequence identity over its entire length to the nucleic acid molecule of (a) or (b)

, wherein said nucleic acid molecule of (a), (b), (c) or (d) is differentially expressed in prostate cancer tissue.

Attorney Docket No.: DEX-0293
Inventors: Salceda et al.
Serial No.: 09/995,494
Filing Date: November 27, 2001
Page 11

Claim 2 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.

Claim 3 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.

Claim 4 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.

Claim 5 (original): The nucleic acid molecule according to claim 4, wherein the nucleic acid molecule is a human nucleic acid molecule.

Claim 6: (canceled)

Claim 7 (original): A vector comprising the nucleic acid molecule of claim 1.

Claim 8 (original): A host cell comprising the vector according to claim 7.

Attorney Docket No.: DEX-0293
Inventors: Salceda et al.
Serial No.: 09/995,494
Filing Date: November 27, 2001
Page 12

Claim 9 (original): A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and (b) incubating the host cell under conditions in which the polypeptide is produced.

Claims 10-14 (canceled) .

Claim 15 (currently amended): A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 ~~or a polypeptide of claim 6~~ in a sample of a patient.

Claims 16-17: (canceled)

Claim 18: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 encoding SEQ ID NO:96.

Claim 19: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 comprising SEQ ID NO:42.

Attorney Docket No.: DEX-0293
Inventors: Salceda et al.
Serial No.: 09/995,494
Filing Date: November 27, 2001
Page 13

Claim 20: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 comprising SEQ ID NO:43.

Claim 21: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 having at least 95% sequence identity over its entire length to the nucleic acid molecule of (a) or (b).

Claim 22: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 having at least 98% sequence identity over its entire length to the nucleic acid molecule of (a) or (b).

Claim 23: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 having at least 99% sequence identity over its entire length to the nucleic acid molecule of (a) or (b).

Claim 24: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 having at least 99.5% sequence identity over its entire length to the nucleic acid molecule of (a) or (b).

Attorney Docket No.: DEX-0293
Inventors: Salceda et al.
Serial No.: 09/995,494
Filing Date: November 27, 2001
Page 14

Claim 25: (new) The isolated prostate cancer specific nucleic acid molecule of claim 1 having at least 99.9% sequence identity over its entire length to the nucleic acid molecule of (a) or (b).